Table 2.
Tachyarrhythmia, Intervention, and Outcomes in Patients Hospitalized With MIS‐C and Acute COVID‐19 in 63 US Hospitals Participating in the “Overcoming COVID‐19” Public Health Registry, March 15, 2020, to December 31, 2021
| All patients (n=63) | Patients with MIS‐C (n=41) | Patients with acute COVID‐19 (n=22) | SVT (n=28) | Accelerated junctional rhythm (n=9) | Ventricular tachycardia (n=38) | |
|---|---|---|---|---|---|---|
| Days from symptoms to arrhythmia onset | 6 (4, 9.5) | 7 (5, 9) | 5 (2, 14) | 6 (4, 9) | 5 (5, 7) | 7 (4, 12.5) |
| Days from hospitalization to arrhythmia onset | 2 (0, 5) | 2 (1, 4) | 2 (0, 6.25) | 2 (0, 3) | 1 (0.25, 1) | 2 (1, 8.5) |
| Duration of arrhythmia, d | 1 (0, 3) | 1 (0, 3) | 1 (0, 3) | 1 (0, 4) | 1 (0, 3) | 1 (0, 4) |
| Arrhythmia interventions | ||||||
| None | 26 (41) | 20 (49) | 6 (27) | 9 (32) | 4 (44) | 15 (39) |
| Antiarrhythmic medication | 31 (49) | 17 (41) | 14 (64) | 15 (54) | 3 (33) | 20 (53) |
| Electrical cardioversion | 11 (17) | 5 (12) | 6 (27) | 8 (29) | 0 (0) | 4 (11) |
| CPR | 8 (13) | 4 (10) | 4 (18) | 2 (7) | 2 (22) | 8 (21) |
| ECMO* | 9 (14) | 6 (15) | 3 (14) | 4 (14) | 4 (44) | 8 (21) |
| Outcomes | ||||||
| Discharged home without antiarrhythmic medication | 38 (60) | 28 (68) | 10 (45) | 16 (57) | 6 (67) | 21 (55) |
| Discharged home with antiarrhythmic medication | 14 (22) | 10 (24) | 4 (18) | 8 (29) | 1 (11) | 9 (24) |
| Transferred to other facility | 2 (3) | 1 (2) | 1 (5) | 2 (7) | 1 (11) | 0 |
| Died | 9 (14) | 2 (5) | 7 (32) | 2 (7) | 1 (11) | 8 (21) |
n (%) or median (Q1, Q3). CPR indicates cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; MIS‐C, multisystem inflammatory syndrome in children; and SVT, supraventricular tachycardia.
*
Includes ECMO cannulation specifically used for treatment of tachyarrhythmia.